Puma Biotech (PBYI) Reports Q3 EPS of $0.17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BofA/Merrill Lynch Downgrades Puma Biotechnology (PBYI) to Underperform
November 2, 2018 9:18 AM EDTBofA/Merrill Lynch analyst Ying Huang downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to Underperform with a price target of $25.00 (from $92.00).
The analyst cites weak Nerlynx sales for the dramatic reversal of opinion.
For an analyst ratings summary and ratings history... More
JPMorgan Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 5:55 AM EDTJPMorgan analyst Cory Kasimov downgraded Puma Biotechnology (NASDAQ: PBYI) from Neutral to Underweight with a price target of $23.00 (from $83.00).
The analyst is incrementally more negative citing the "significantly tempered" expectations on Nerlynx.
For an analyst ratings summary and ratings history on... More
Barclays Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 4:32 AM EDTBarclays analyst Gena Wang downgraded Puma Biotechnology (NASDAQ: PBYI) from Equalweight to Underweight with a price target of $29.00 (from $72.00).
The analyst steps aside citing the Q3 revenue miss along with a lack of growth clarity on Nerlynx.
For an analyst ratings... More
